SCENESSE

This brand name is authorized in Austria, Estonia, Finland, Croatia, Ireland, Italy, Lithuania, Netherlands, Poland, United Kingdom, United States

Active ingredients

The drug SCENESSE contains one active pharmaceutical ingredient (API):

1 Afamelanotide UNII QW68W3J66U - AFAMELANOTIDE

Afamelanotide is a synthetic tridecapeptide and a structural analogue of α-melanocyte stimulating hormone (α-MSH). Afamelanotide is a melanocortin receptor agonist and binds predominantly to the melanocortin-1 receptor (MC1R). Afamelanotide is thought to mimic the endogenous compound’s pharmacological activity by activating the synthesis of eumelanin mediated by the MC1R receptor. Eumelanin contributes to photoprotection through different mechanisms. Read about Afamelanotide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SCENESSE Implant	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
D02BB02		D Dermatologicals → D02 Emollients and protectives → D02B Protectives against UV-radiation → D02BB Protectives against UV-radiation for systemic use
Discover more medicines within D02BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1673928
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 393360
Country: IT	Agenzia del Farmaco	Identifier(s): 043798014
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1075287
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 134384
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100334761
Country: US	FDA, National Drug Code	Identifier(s): 73372-0116